Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | CEL | P19835 | 2/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2050408 | 0.77 | OPRL1 (0.35) | GRIA1CACNG8TP53RECQLTAS1R3 | |
| SCHEMBL96213 | 0.76 | CYP1A2 (0.43) | — | |
| SCHEMBL16797106 | 0.74 | TP53 (0.46) | GRIA1CACNG8TP53RECQLTAS1R3 | |
| SCHEMBL9232062 | 0.73 | TP53 (0.50) | GRIA1CACNG8TP53RECQLHTR1A | |
| SCHEMBL1273995 | 0.73 | HTR2A (0.48) | GRIA1CACNG8TP53RECQLHTR1A | |
| SCHEMBL1897406 | 0.72 | TP53 (0.57) | TP53RECQLOPRL1ADRA1AGRM2 | |
| SCHEMBL3785910 | 0.71 | SMN1; SMN2 (0.41) | GRIA1CACNG8TP53RECQLOPRL1 | |
| Charcoal, Activated SCHEMBL5897477 | 0.70 | TP53 (0.55) | TP53RECQLOPRL1ADRA1AGRM2 | |
| SCHEMBL2047547 | 0.69 | TAS1R3 (0.44) | GRIA1CACNG8TP53RECQLTAS1R3 | |
| SCHEMBL21388492 | 0.69 | HTR2C (0.48) | GRIA1CACNG8TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080090-B1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-01-31 | — | — | EP | claimed |
| US-9682977-B2 | Bicyclic heteroaryl indole analogues useful as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-06-20 | — | — | US | claimed |
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-11-10 | — | — | US | claimed |
| EP-3080090-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2016-10-19 | — | — | EP | claimed |
| CN-105980364-A | Bicyclic heteroaryl indole analogs useful as ROR γ modulators | 格兰马克药品股份有限公司 | 2016-09-28 | — | — | CN | claimed |
| WO-2015087234-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-06-18 | — | — | WO | claimed |
| EP-3080090-B1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-01-31 | — | — | EP | disclosed |
| US-9682977-B2 | Bicyclic heteroaryl indole analogues useful as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-11-10 | — | — | US | disclosed |
| EP-3080090-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2016-10-19 | — | — | EP | disclosed |
| CN-105980364-A | Bicyclic heteroaryl indole analogs useful as ROR γ modulators | 格兰马克药品股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2015087234-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015052675-A1 | SUBSTITUTED DIHYDRO-BENZIMIDAZOLE COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | RORA, RORB, RORC | GRIA1 197/4885CACNG8 581/4885TP53 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.